Literature DB >> 19723294

Perspectives on recent advances in the understanding and treatment of Parkinson's disease.

A H Schapira1, Y Agid, P Barone, P Jenner, M R Lemke, W Poewe, O Rascol, H Reichmann, E Tolosa.   

Abstract

There have been numerous important recent advances in our understanding of the causes of Parkinson's disease (PD), the treatments available and how these are best applied for the long-term management of patients. Novel genes causing familial PD have been discovered and mechanisms leading to cell dysfunction and death identified. The PD prodrome is now a subject of great interest and clinical markers are being defined that may in future, together with biochemical markers, support an early, pre-motor diagnosis of PD. This will become important as new therapies are developed to modify disease progression. In the interim, the optimization of existing therapies remains an important priority. The value of existing and novel continuous drug delivery systems in PD is seen as providing simplified regimens, maintenance of motor control, reduction in motor complications and improved patient adherence to drug use.

Entities:  

Mesh:

Year:  2009        PMID: 19723294     DOI: 10.1111/j.1468-1331.2009.02793.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  23 in total

Review 1.  Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Authors:  Anthony H V Schapira
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease.

Authors:  Giselle M Petzinger; Beth E Fisher; Sarah McEwen; Jeff A Beeler; John P Walsh; Michael W Jakowec
Journal:  Lancet Neurol       Date:  2013-07       Impact factor: 44.182

Review 4.  Aetiopathogenesis of Parkinson's disease.

Authors:  Anthony H V Schapira
Journal:  J Neurol       Date:  2011-05       Impact factor: 4.849

5.  Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease.

Authors:  Giuseppa Mudò; Johanna Mäkelä; Valentina Di Liberto; Timofey V Tselykh; Melania Olivieri; Petteri Piepponen; Ove Eriksson; Annika Mälkiä; Alessandra Bonomo; Minna Kairisalo; Jose A Aguirre; Laura Korhonen; Natale Belluardo; Dan Lindholm
Journal:  Cell Mol Life Sci       Date:  2011-10-08       Impact factor: 9.261

Review 6.  Early versus delayed initiation of pharmacotherapy in Parkinson's disease.

Authors:  Matthias Löhle; Carl-Johan Ramberg; Heinz Reichmann; Anthony H V Schapira
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 7.  Parkinson's disease as a disconnection syndrome.

Authors:  Alice Cronin-Golomb
Journal:  Neuropsychol Rev       Date:  2010-04-10       Impact factor: 7.444

Review 8.  Stem cell therapies in age-related neurodegenerative diseases and stroke.

Authors:  Yuan Wang; Xunming Ji; Rehana K Leak; Fenghua Chen; Guodong Cao
Journal:  Ageing Res Rev       Date:  2016-11-19       Impact factor: 10.895

9.  Evaluating rehabilitation interventions in Parkinson's disease with functional MRI: a promising neuroprotective strategy.

Authors:  Carlo Augusto Mallio; Bruno Beomonte Zobel; Carlo Cosimo Quattrocchi
Journal:  Neural Regen Res       Date:  2015-05       Impact factor: 5.135

10.  Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.

Authors:  Brian P Dranka; Alison Gifford; Anamitra Ghosh; Jacek Zielonka; Joy Joseph; Anumantha G Kanthasamy; Balaraman Kalyanaraman
Journal:  Neurosci Lett       Date:  2013-05-28       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.